SWEDEN, 6th December, 2021 — Omnio AB is developing new drug products based on the proinflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5MSEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to now initiate its planned activities to develop recombinant plasminogen for treatment of diabetic foot ulcers.

“We are delighted with the response that we received in connection with the capital raise during this period. Both existing and new capital-strong shareholders have shown great confidence in the company”, says Omnio AB’s CEO Ulrika Norin. Omnio AB is a spin-off from Umeå University, Sweden, focusing on wound healing. The company is
based on a series of conceptual breakthroughs in plasminogen research led by Professor Tor Ny at
Umeå Universitet. Omnio has shown that plasminogen is a pro-inflammatory regulator of inflammation
that can be used to treat chronic wounds where inflammation is dysfunctional.
Non-healing chronic wounds is a major global health problem and constitute a significant burden for
patients, healthcare professionals and the healthcare system. Most problematic are diabetic ulcers,
venous ulcers, and pressure ulcers. Over 50% of all lower extremity amputations are caused by nonhealing
diabetic foot ulcers (DFUs). World-wide more than 10 million patients are amputated because of
non-healing DFUs. With an aging population and increasing incidence of diabetes type 2 worldwide,
DFUs will continue to compose a high economic and societal burden.
In the new share issue the company welcomed Swedish and Dutch seasoned investors with a strong
track record of investments in life science companies.
”The added investments make it possible for the company to now continue its planned activities and one
step closer to bringing transformative treatment to DFU patients in need”, says Ulrika Norin.